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Myokines are specialized cytokines that are secreted from skeletal muscle (SKM) in
response to metabolic stimuli, such as exercise. Interleukin-15 (IL-15) is a myokine
with potential to reduce obesity and increase lean mass through induction of metabolic
processes. It has been previously shown that IL-15 acts to increase glucose uptake
in SKM cells. However, the downstream signals orchestrating the link between IL-15
signaling and glucose uptake have not been fully explored. Here we employed the
mouse SKM C2C12 cell line to examine potential downstream targets of IL-15-induced
alterations in glucose uptake. Following differentiation, C2C12 cells were treated
overnight with 100 ng/ml of IL-15. Activation of factors associated with glucose
metabolism (Akt and AMPK) and known downstream targets of IL-15 (Jak1, Jak3,
STAT3, and STAT5) were assessed with IL-15 stimulation. IL-15 stimulated glucose
uptake and GLUT4 translocation to the plasma membrane. IL-15 treatment had no
effect on phospho-Akt, phospho-Akt substrates, phospho-AMPK, phospho-Jak1, or
phospho-STAT5. However, with IL-15, phospho-Jak3 and phospho-STAT3 levels were
increased along with increased interaction of Jak3 and STAT3. Additionally, IL-15 induced
a translocation of phospho-STAT3 from the cytoplasm to the nucleus. We have evidence
that a mediator of glucose uptake, HIF1α, expression was dependent on IL-15 induced
STAT3 activation. Finally, upon inhibition of STAT3 the positive effects of IL-15 on glucose
uptake and GLUT4 translocation were abolished. Taken together, we provide evidence
for a novel signaling pathway for IL-15 acting through Jak3/STAT3 to regulate glucose
metabolism.
Keywords: myokines, skeletal muscle glucose uptake, Jak/STAT, AMPK, IL-15
INTRODUCTION
Obesity is a major problem in our modern society, its prevalence continues to grow, and it is
linked to many disease processes, such as diabetes, cardiovascular disease, and certain cancers
(Félix-Redondo et al., 2013; Ogden et al., 2014). A multitude of studies have been underway to
uncover regulators of metabolism with the intent of treating and/or preventing obesity and its
associated disease states (Hampton, 2012; Pedersen and Febbraio, 2012; Egan and Zierath, 2013;
Febbraio, 2014). It has long been known that increasing skeletal muscle (SKM) mass and activity
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are routes to induce energy expenditure for the reduction of
adiposity and improvements in insulin resistance (Ivy et al., 1986;
Kraegen et al., 1989; Pedersen and Febbraio, 2012). Recently,
SKM has proven to possess functions beyond muscle contraction
(Pedersen and Febbraio, 2012). Many cytokines secreted from
skeletal muscle, termed “myokines,” have been identified and
muscle contraction appears to be a major stimulator of their
release (Pedersen, 2013; Raschke and Eckel, 2013; Catoire
et al., 2014; Eckardt et al., 2014). Multiple myokines, BDNF5,
FGF21, irisin, and interleukin-6 (IL-6), among others, have
been shown to exert their positive metabolic actions in an
endocrine/paracrine manner (Fisher ffolliott et al., 2012; Raschke
and Eckel, 2013; Catoire et al., 2014; Indrakusuma et al., 2015).
Interleukin-15 (IL-15) is a myokine that has shown promise
for the prevention and/or treatment of obesity and metabolic
disorders (Alvarez et al., 2002; Argilés et al., 2009; Quinn
and Anderson, 2011; Sun and Liu, 2015). Historically, IL-15
has been regarded as an activator of natural killer (NK) cells
and has been viewed as pro- and anti-inflammatory with anti-
tumorigenic potential (Castillo and Schluns, 2012; Lutz and
Quinn, 2012). IL-15 belongs to a 4-α-helix bundle cytokine family
alongside a variety of other interleukins that are within this
family (Budagian et al., 2006; Waldmann, 2015). Expression of
the gene encoding for IL-15 results in the translation of two
isoforms, a short 21-amino acid and a long 48-amino acid signal
peptide (Quinn and Anderson, 2011). The long IL-15 isoform
combines intracellularly with its receptor, IL-15Rα, prior to
secretion from SKM (Budagian et al., 2006; Quinn and Anderson,
2011). Subsequently, the cytokine-receptor complex either trans-
presents or binds to the β and γ chains of the IL-2 receptor
on its target tissues for initiation of IL-15 signaling (Budagian
et al., 2006; Castillo and Schluns, 2012). Alternatively, IL-15
can form a heterodimer with the IL-2 receptor independent
of IL-15Rα (Castillo and Schluns, 2012). Importantly, there is
evidence that the appearance of IL-15 in circulation increases
following exercise, in humans and rodents, although this notion
is somewhat controversial (Gray and Kamolrat, 2011; Catoire
et al., 2014; Rinnov et al., 2014; Crane et al., 2015; Pierce et al.,
2015).
Increased circulating levels of IL-15 have been implicated
in stimulating expression of mitochondrial associated factors,
such as PPARs and SIRT1, in mouse SKM (Almendro et al.,
2008; Quinn et al., 2012, 2013; O’Connell and Pistilli, 2015).
Additionally, IL-15 has the ability to stimulate both glucose
uptake and fatty acid oxidation in SKM cells (Busquets
et al., 2006). Further, transgenic mice with increased IL-15 in
circulation display an increased endurance capacity phenotype
(Quinn et al., 2012). However, recent in vivo studies have
questioned the relevance of IL-15 secretion following exercise in
humans (Pierce et al., 2015). Although it has been demonstrated
that IL-15 induces metabolic pathways in SKM, the discrete
molecular mediators of these effects have not been fully defined.
Themost well studied pathway for IL-15 action is the janus kinase
activation of signal transducer and activator of transcription
proteins (Jak/STAT) signaling pathway (Waldmann, 2015; Ye,
2015). Upon IL-15 binding to the IL-2 receptor, Jak isoforms
(Jak1 and/or Jak3) are auto-phosphorylated and in turn induce
phosphorylation of STAT3 and/or STAT5 (Ye, 2015). Overall the
Jak/STAT signaling pathway has a large number of intracellular
functions with the potential to effect energy metabolism in
many cell types (Frias and Montessuit, 2013; Richard and
Stephens, 2014; Ye, 2015). Alternatively, pathways aside from
the Jak/STAT signaling cascade have been linked to IL-15 action
(Stone et al., 2011; Zhao and Huang, 2012; Crane et al., 2015;
Waldmann, 2015). For instance, it has been established that
the PI3K/Akt pathway becomes activated downstream of IL-
15 action (Budagian et al., 2006; Zhao and Huang, 2012; Lai
et al., 2013; Waldmann, 2015; Ye, 2015). Additionally, a link
between the energy sensing enzyme AMP-activated protein
kinase (AMPK) and IL-15 has been established by us and
others (Abbott et al., 2012; Turcotte and Abbott, 2012; Crane
et al., 2015). Both Akt and AMPK signaling exert beneficial
effects on substrate metabolism such as glucose uptake and fatty
acid oxidation in SKM cells, in line with IL-15 action (Thorell
et al., 1999). However, little is known regarding the signaling
pathway downstream of IL-15-IL-2 receptor interaction, to
mediate substrate metabolism in SKM cells.
Overall, there is strong evidence that IL-15 plays a positive
role in mediating SKM substrate utilization (Busquets et al., 2006;
Argilés et al., 2009; Quinn and Anderson, 2011). However, the
signaling molecules responsible for orchestrating IL-15 action on
energy metabolism have yet to be firmly established in SKM. The
purpose of this study was to identify the molecular pathways
that mediate the downstream effects of IL-15 signaling in SKM
cells. Here, we demonstrate that IL-15 increases glucose uptake
and GLUT4 translocation, through induction of the Jak3/STAT3
signaling pathway in SKM cells.
METHODS
C2C12 Cell Culture
The immortalized mouse SKM fibroblast line, C2C12 (Sigma),
was cultured in DMEM supplemented with 10% fetal bovine
serum (FBS; Sigma), 1% Penicillin-Streptomycin (10,000 U/mL;
Corning), and 0.1% Amphotericin B (Corning). At 80%
confluence, cells were induced toward differentiation to mature
myotubes with DMEM supplemented with 2% horse serum
(Sigma) and 1 µM insulin (Sigma) for 6 days. Differentiation
was confirmed by visualization of myotube formation. On the
fifth day of differentiation cells were treated with 100 ng/ml of
recombinant IL-15 (Genscript) for 24 h, as previously described
(Abbott and Turcotte, 2014; Thornton et al., 2016).
Glucose Uptake Assay
Glucose uptake was measured in fully differentiated C2C12
cells using a non-radioactive fluorometric assay, as previously
described (Leira et al., 2002; Zou et al., 2005; Kanwal et al.,
2012). Briefly, following differentiation in 6 well plates, cells were
serum starved in growth media for 2 h and cells were treated
with either vehicle control, IL-15 100 ng/ml, insulin (100 nM),
a STAT3 inhibitor (100 µM; S31-201; Sigma), or IL-15 + S31-
20 with or without 50 µM 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-
4-yl)Amino)-2-Deoxyglucose (2-NBDG) (Cayman Chemical) in
Krebs-Henseleit buffer containing 0.1% fatty acid free BSA
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(Sigma) and 2000 mg/L of glucose at 37◦C with 5% CO2
(Siddiquee et al., 2007; Kelly et al., 2010). Following 2 h, the
cells were lysed in PBS-Triton-X100 buffer and florescence was
measured using a microplate reader with excitation 488 nm
and emission 520 nm. The concentration of NBDG uptake was
calculated from a standard curve of NBDG in lysis buffer. Values
were normalized to the protein content present in the cell lysates.
Western Blot Analysis
C2C12 cells were lysed in a modified RIPA buffer supplemented
with protease inhibitors (Pierce) (Abbott et al., 2009). For
nuclear fractionation, cells were lysed with a commercially
available kit and cytosolic and nuclear fractions were recovered
(Pierce) (Abbott et al., 2012). Total protein was assessed using
a standard Bradford assay (BioRad). Approximately 20 µg of
protein from the cell homogenate preparations were separated on
a 4–12% gradient gel (GenScript) via SDS-PAGE. Proteins were
transferred onto Immobilon-P polyvinylidene difluoride (PVDF)
membranes and blocked with 5% BSA in Tween-TBS for 1 h The
membranes were then incubated (4◦C) in 5% BSA in Tween-
TBS with antibodies (1:1000) against phospho-AMPK-Thr172,
total AMPK, phospho-Akt-Thr308, phospho-Akt substrate, total
Akt, phospho-Jak1, total Jak1, phospho-Jak3, total Jak3, phospho-
STAT3-Tyr705, total STAT3, phospho-STAT5, total STAT5
(Cell Signaling), GLUT4 (Santa Cruz), and GAPDH (Sigma).
Following overnight incubation, the membranes were then
probed with a secondary antibody (Genscript, 1:2000; or Thermo,
1:10,000). Blots were then washed and subjected to enhanced
chemiluminescence (Pierce). Band density was quantified using
Image J and normalized to control samples. Membranes were
stripped in 0.5 M NaOH for 15 min at room temperature,
followed by three 5 min washes in TBS-T, and subsequently
probed for total proteins and subsequently GAPDH (Sigma) was
used as a loading control.
Immunofluorescence
After overnight IL-15 experimental treatment, the C2C12
cells were fixed with ice cold methanol. Cells were blocked
with 5% BSA in PBS-Tween followed by a series of washes.
Cells were incubated overnight in a humidified chamber with
primary antibodies (GLUT4 or pSTAT3) at 4◦C. Alexaflour-
488 (Molecular Probes) secondary antibodies were used and
DAPI was used as a nuclear stain. Cells were imaged using a
Zeiss inverted microscope and images were captured with an
Axiovision camera. Quantification of GLUT4 on the plasma
membrane and co-localization of STAT3 to the nuclei was
performed using Image J and Fiji software (Schindelin et al., 2012;
Schneider et al., 2012).
Immunoprecipitation
After the experimental treatments, cells were lysed as described in
Western blot analysis and Jak3 specific antibodies (Cell Signaling)
were added to the lysate (250 ug) and incubated overnight at
4◦C, as previously described (Abbott et al., 2009; Bogachus and
Turcotte, 2010; Ahmadian et al., 2011). Protein A/G agarose
beads were added and the slurry was incubated for 2–4 h
at 4◦C (Santa Cruz Biotechnology). The immunoprecipitates
were collected by centrifugation and pellets were washed with
PBS buffer, and the final supernatants were resuspended in
SDS-sample buffer (Genscript). Subsequently western blotting
procedures were carried out as previously described and
antibodies specific to STAT3 (Cell Signaling) were used. Ponceau
S was applied to the membranes to verify equal protein loading.
Real Time PCR
Standard RNA isolation procedures were performed on the
cells following the 6 day treatment protocol, as previously
described (Pedersen and Febbraio, 2012; Ogden et al., 2014).
Briefly, cells were lysed with Trizol reagent and chloroform
was added to separate the RNA from the DNA and protein
fractions. RNA was precipitated from the clear phase of
the Trizol-chloroform mixture, followed by centrifugation at
12,000 g at 4◦C, with isopropanol. The RNA pellet was washed
with 75% ethanol, centrifuged at 7500 g for 5 min, at 4◦C,
and the pellets were air-dried. Using RNAse-free water, the
pellets were resuspended and the RNA purity and concentration
were quantified using a Nano-Drop spectrophotometer. Reverse
transcription of RNA to cDNA was performed on 2 ug of
RNA using SuperScript reverse transcriptase VILO kit. Real time
qPCR was performed on the cDNA, using SYBR-green in a 96
well plate. Primer sequences for HIF1α, SOCS3, and GAPDH
are listed in Table 1. GAPDH was used as an internal control
and the ddCT method was used to calculate gene expression
levels.
Statistics
Statistical analysis was carried out using GraphPad Prism 6.0
software. Values are displayed as means± SEM. Each experiment
consisted of 3 internal replicates and then were repeated 2–3
times for a total n = 6–9 for each experimental group. IL-15
treatment values were compared to vehicle control cells and
a Student’s T-test was calculated with P < 0.05 considered
to be statistically significant. For glucose uptake assessments a
One-way ANOVA was used with a Fisher’s post hoc analysis
and a P-value of < 0.05 was considered to be statistically
significant.
RESULTS
IL-15 Promotes GLUT4 Translocation and
Glucose Uptake
In line with previously reported data (Busquets et al., 2006),
IL-15 treatment resulted in an increase in glucose uptake
TABLE 1 | Primer sequences used for qPCR analysis.
Gene Sequence
HIF1α—F GCACTAGACAAAGTTCACCTGAGA
HIF1α—R CGCTATCCACATCAAAGCAA
SOCS3—F ATTTCGCTTCGGGACTAGC
SOCS3—R AACTTGCTGTGGGTGACCAT
Gapdh—F AGGTCGGTGTGAACGGATTTG
Gapdh—R TGTAGACCATGTAGTTGAGGTCA
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FIGURE 1 | Effect of IL-15 signaling on glucose uptake and GLUT4. (A)
Glucose uptake with IL-15 using a 2-NBDG non-radioactive assay; (B)
western blotting of GLUT4 protein expression in whole cell lysates; (C)
immunofluorescence of GLUT4 in the fully differentiated myotubes; (D)
quantification of GLUT4 expression as indicated by fluorescence within the
total cell area; (E) percent of GLUT4 expression in the plasma membrane
relative to the total GLUT4 within the cell. Assessments were carried out on
differentiated C2C12 myotubes following 24 h treatment with 100 ng/ml of
IL-15 for the western blotting. All values are displayed as means ± SEM, n = 6
per group, *P < 0.05, **P < 0.005.
by 49% when compared to the control SKM cells (P <
0.05; Figure 1A). However, unlike mRNA expression data
reported by others (Busquets et al., 2006), there was no
significant effect of IL-15 on the total cell protein content of
GLUT4 (P > 0.05; Figure 1B). Conversely, IL-15 treatment
stimulated a translocation of GLUT4 from the intracellular
compartment to the plasma membrane of the fully differentiated
SKM myotubes (Figure 1C). Similar to the western blot
expression there were no differences in the quantifiable
immunofluorescence of GLUT4 in total cell area (P > 0.05;
Figure 1D). However, the percentage of GLUT4 present on
the plasma membrane relative to the total GLUT4 expression
was significantly greater in the IL-15 treated cells (P < 0.05;
Figure 1E).
IL-15 Mediated Effects on Enzyme
Activation and Protein Expression of IL-2R
Targets
Despite previous evidence that IL-15 may signal through Akt
in lymphocytes, we were unable to detect any alterations
in phospho-Akt or total Akt protein expression (P > 0.05;
Figure 2A, (Lai et al., 2013; Waldmann, 2015)). Further, the
phosphorylation state of downstream substrates (TBC1D1 and
TBC1D4) of Akt were also not altered with IL-15 (P >
0.05; Figure 2A). AMPK is a master metabolic regulator and
is confirmed to stimulate GLUT4 translocation along with
glucose uptake (Winder and Hardie, 1999; Abbott et al., 2009).
Additionally, a link between AMPK and IL-15 has been identified
by us and others (Abbott et al., 2012; Crane et al., 2015). However,
there were no alterations in phosphorylated AMPK at Thr179 or
total protein expression of AMPKwith IL-15 treatment (P> 0.05;
Figure 2B).
Because IL-15 shares a receptor with IL-2, we attempted
to examine potential signaling molecules directly downstream
of the IL-2 receptor in SKM cells (Budagian et al., 2006;
Waldmann, 2015). A widely studied route of IL-15 signaling is
through activation of the Jak/STAT pathway (Mishra et al., 2014b;
Waldmann, 2015). However, IL-15 treatment failed to induce an
increase in phosphorylation of Jak1 at Tyr1022/1023 (P > 0.05;
Figure 2C). Likewise, there were no effects of IL-15 treatment
in regards to total protein expression of Jak1 (Figure 2C).
Conversely, in the presence of IL-15, phosphorylation of Jak3 at
Tyr980/981 was increased (130%) with no alterations in its total
protein expression (P < 0.05; Figure 2D).
STAT5 is a known down-stream effector of Jak3 signaling,
but phosphorylation of STAT5 at Tyr694 remained unchanged
with the IL-15 treatment protocol (P > 0.05; Figure 3A). A
less studied target of Jak3 is STAT3 and we measured increased
phosphorylation of STAT3 at Tyr705, nearly 4-fold, with IL-
15 (P < 0.05; Figure 3B). We also measured increased (57%)
interaction between Jak3 and STAT3 in the presence of IL-15
(P < 0.05; Figure 3C). STAT3 has been shown to translocate
to the nucleus, upon phosphorylation at Tyr705, to carry out
its transcriptional activities (Tammineni et al., 2013). Here we
measured a 3-fold increase in phosphorylated (Tyr705) STAT3
in the nuclear fraction as assessed by western blotting and
immunofluorescence (P < 0.05; Figures 4A,B). The increases in
phospho-STAT3 on the nuclear fraction corresponded to a 62%
reduction of phospho-STAT3 in the cytosolic fraction (P < 0.05;
Figure 4A).
Involvement of STAT3 in Mediating IL-15
Induced Glucose Uptake
In order to determine the necessity of STAT3 activation for
mediating IL-15 induced glucose uptake, we used a STAT3
inhibitor. Inhibition of STAT3 in the SKM cells was verified
by western blotting of pSTAT3 (P < 0.05; Figure 5A). When
STAT3 was inactivated, the IL-15 induced increases in glucose
uptake were abolished when compared to vehicle control cells
(P < 0.05; Figure 5B). It should be noted that addition of
the vehicle control (DMSO) in the inhibitor studies yielded
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FIGURE 2 | Effects of IL-15 signaling on mediators of glucose uptake
and proteins downstream of IL-2βγ receptor signaling. Western blotting
of (A) phospho-Akt-Thr308, TBCD1, TBCD4, and total Akt; (B)
phospho-AMPK-Thr172 and total AMPK; (C) phospho-Jak1 and total Jak1;
(D) phospho-Jak3 and total Jak3. Assessments were carried out on whole cell
lysates from differentiated C2C12 myotubes following 24 h treatment with 100
ng/ml of IL-15. GAPDH was used as a loading control for western blotting.
Vehicle cells were used as a control to calculate protein expression. Image J
was used to quantify band density in western blotting experiments. All values
are displayed as means ± SEM, n = 6–9 per group, *P < 0.05.
alterations in the relative amounts of glucose uptake when
compared to non-DMSO treated cells (Figure 1A). STAT3
has previously been shown to mediate glucose up through
HIF1α induced translocation of GLUT4 (Demaria et al., 2010;
Sakagami et al., 2014). Indeed IL-15 induced an increase in
mRNA expression levels of HIF1α and these effects were
prevented with STAT3 inhibition in the presence of IL-15
(P < 0.05; Figure 5C). Conversely, IL-15 had no effect on
SOCS3 mRNA expression levels, while as expected, inhibition
of STAT3 yielded reductions in SOCS3 expression levels
(Figure 5D). Inhibition of STAT3 had no effects on total cellular
GLUT4 expression (P > 0.05; Figure 6A). However, the IL-
15 induced translocation of GLUT4 to the plasma membrane
was abolished with STAT3 inhibition in combination with
IL-15, as measured by percentage of GLUT4 on the plasma
FIGURE 3 | Effects of IL-15 on STAT activation. Western blotting of (A)
phospho-STAT5 and total STAT5; (B) phospho-STAT3 at Tyr705 and total
STAT3; (C) immunoprecipitation of Jak3 and subsequent western blotting of
STAT3. Assessments were carried out on differentiated C2C12 myotubes
following 24 h treatment with 100 ng/ml of IL-15. GAPDH was used as loading
control for western blotting. Ponceau S was used as a loading control for the
immunoprecipitation analysis. Vehicle cells were used as a control to calculate
protein expression. Image J was used to quantify band density in western
blotting experiments. All values are displayed as means ± SEM, n = 6 per
group, *P < 0.05.
membrane relative to the total cell GLUT4 expression (P < 0.05;
Figures 6B,C).
DISCUSSION
Data from this study solidifies the notion that the myokine
IL-15 is directly involved in mediating glucose metabolism
in SKM. Here we have brought to light a comprehensive
signaling mechanism for IL-15 action in SKM cells. Our data
shows that IL-15 promotes translocation of GLUT4 to the
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FIGURE 4 | IL-15 induced activation and translocation of STAT3. (A)
Phospho-STAT3 at Tyr705 in the nuclear and cytosolic fractions; and (B)
representative image of phospho-STAT3 co-localization with nuclei by
immunoflouresence. Assessments were carried out on differentiated C2C12
myotubes following 24 h treatment with 100 ng/ml of IL-15. Nuclear specific
Histone 3 (H3) was used as verification of purity of nuclear fractions. Vehicle
cells were used as a control to calculate protein expression. Image J was used
to quantify band density in western blotting experiments. All values are
displayed as means ± SEM, n = 6 per group, **P < 0.05.
plasma membrane, accounting for the increase in glucose
uptake. Additionally, our data indicates that IL-15 signals
through the Jak3/STAT3 signaling pathway, without activation
of other established downstream signals of IL-2R, in SKM cells.
Moreover, we show for the first time that IL-15 promotes the
translocation of phosphorylated STAT3 to the nucleus. The IL-
15 induced translocation of STAT3 might provide insight into
the molecular mechanism behind the stimulatory effect of IL-
15 on overall cellular metabolism. Importantly, we uncovered
a role for IL-15 induced STAT3 activation to induce HIF1α
expression, leading to an increase in GLUT4 translocation to the
plasma membrane. Altogether, we provide evidence that IL-15
signaling in SKM is tightly regulated through coordination of the
Jak3/STAT3 signaling pathway to promote GLUT4 translocation
and consequently glucose uptake.
IL-15 has been extensively studied in tissues and cells other
than SKM cells, such as NK lymphocytes (Lai et al., 2013;
Mishra et al., 2014a). IL-15 signaling is complex, in that, it is
ubiquitously expressed, but its secretion is proposed to be limited
to SKM, and it is secreted with its receptor, IL-15Rα (Budagian
et al., 2006; Catoire et al., 2014). Complicating IL-15 signaling
is its ability to trans-present in combination with IL-15Rα to
neighboring cells (Castillo and Schluns, 2012; Waldmann, 2015).
Nevertheless, once released into circulation the IL-15/IL-15Rα
complex binds, or IL-15 acting alone, to the IL-2Rβ/γ chains on
its target tissue (Giri et al., 1995). It has repeatedly been shown
FIGURE 5 | Importance of STAT3 in IL-15 induced glucose uptake. (A)
inhibition of STAT3 was verified by western blotting against phospho-STAT3;
(B) glucose uptake was assessed in the presence of vehicle control, insulin
(100 nM), IL-15 (100 ng/ml), a STAT3 inhibitor (100 µM; S31-201), or with both
IL-15 and the STAT3 inhibitor (IL-15 + S); (C) HIF1α mRNA expression levels;
(D) SOCS3 mRNA expression levels. All values are displayed as means ±
SEM, n = 6 per group, *P < 0.05 (different from all groups); **P < 0.005
(different from all groups); ****P < 0.0001 (different from all groups); #P < 0.05
(different from IL-15 group).
that IL-15 induces mitochondrial associated factors in various
tissues, such as adipose and SKM (Almendro et al., 2006; Quinn
et al., 2012, 2013; Barra et al., 2014; O’Connell and Pistilli, 2015).
With this in mind, we examined the role of IL-15 signaling in
mediating increases in substrate availability through modulation
of transport proteins. We did not detect any alterations in total
GLUT4 protein expression, which has been hypothesized to be
controlled by IL-15 signaling (Busquets et al., 2006). However,
in line with other studies, we measured increases in glucose
uptake with IL-15 treatment in the SKM cells (Busquets et al.,
2006). Further, we show that IL-15 acts to increase glucose uptake
through induction of translocation of GLUT4 to the plasma
membrane. GLUT4 translocation is a well-studied pathway
and has been shown to occur via multiple regulators, such as
AMPK (Thorell et al., 1999; Viollet et al., 2003). Additionally,
it has been recognized that IL-15 acts upstream of proteins
associated with mitochondrial activity, such as PGC1α, PPARs,
and SIRT1 (Quinn et al., 2008, 2012; O’Connell and Pistilli,
2015). PGC1α and PPAR signaling are downstream targets of
the important energy sensing enzyme, AMPK, and us and
others, have shown a relationship between AMPK and IL-15 in
SKM. We previously showed that treatment with IL-15 reduced
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FIGURE 6 | Importance of STAT3 in IL-15 mediated GLUT4 translocation. (A) GLUT4 expression; (B) percent of GLUT4 expression in the plasma membrane
relative to the total GLUT4 within the cell; (C) immunofluorescence of GLUT4 in myotubes. Cells with treated with either vehicle control, IL-15 (100 ng/ml), a STAT3
inhibitor (100 µM; S31-201), or with both IL-15 and the STAT3 inhibitor (IL-15 + S). All values are displayed as means ± SEM, n = 6 per group, *P < 0.05; **P < 0.005.
phosphorylated AMPK content in SKM cells. However, in those
experiments cells were serum starved, which yields independent
effects on AMPK. In this regard, we maintained our cells, in
the current studies, in growth media including serum, to rule
out signaling pathways beyond IL-15 signaling. Nevertheless,
we hypothesized that the beneficial metabolic effects of IL-15
may signal through activation of AMPK. However, upon IL-
15 treatment, phosphorylation of AMPK remained unchanged
(Abbott et al., 2012; Wan et al., 2014; Crane et al., 2015).
Binding of the IL-15/IL15Rα complex to IL-2Rβ/γ activates
numerous signaling pathways, such as the Akt and Jak/STAT
pathways, among others (Stone et al., 2011; Zhao and Huang,
2012; Lai et al., 2013). We speculated that IL-15 signals through
the Akt signaling pathway, based on previously published
work and our glucose kinetics data (Zhao and Huang, 2012).
Interestingly, we were unable to measure increases in Akt
activation by examination of its phosphorylation state and by
assessing its downstream substrates, TBC1D1 and TBC1D4. The
results of our investigation of Akt are in contradiction to other
studies that point to a link between IL-15 and Akt signaling
in SKM (Zhao and Huang, 2012; Lai et al., 2013). The study
conducted by Zhao and Huang showed that IL-15 treatment,
in combination with Akt overexpression, acted to regulate T-
cell-SKM interaction following denervation (Zhao and Huang,
2012). However, in our study we examined the ability of IL-15
treatment to modulate the activation state of Akt in C2C12 SKM
cells.
Ruling out AMPK and Akt activation, we next examined
the Jak/STAT signaling pathway, which is widely accepted as
a downstream modulator of IL-15/IL-2R signaling (Budagian
et al., 2006; Lai et al., 2013; Waldmann, 2015; Ye, 2015).
Not surprisingly, Jak3 phosphorylation was increased, as Jak3
has repeatedly been shown to be activated by IL-15/IL-2R
signaling in numerous cells (Lai et al., 2013). On the other
hand, some have shown that Jak1 is downstream of IL-15
signaling, but here, we failed to provide a link between IL-15
and Jak1 signaling, which is line with other reports (Kirken
et al., 1995; Lai et al., 2013). Further, IL-15 failed to induce
STAT5 phosphorylation, which is not in agreement with previous
studies, showing STAT5 as downstream of the IL-2R and/or IL-
15 signaling (Lin and Leonard, 2000; Crane et al., 2015). Of
note, little is known about the signaling molecules downstream
of the IL-15 receptor, IL-2R, in SKM cells, which may account
for the discrepancies between our data an others published
in alternate cell types. Nevertheless, our data indicates that
IL-15 signaling induces activation of STAT3, which is in line
with other studies in endothelial cells (Stone et al., 2011).
Importantly, we measured increased Jak3-STAT3 interaction,
presumably to induce STAT3 phosphorylation at Tyr705, in the
IL-15 treated SKM cells. It has been previously determined that
upon phosphorylation and activation, from an upstream Jak,
STAT3 translocates to the nucleus to bind to DNA, inducing its
transcriptional activity (Yahata et al., 2003; Frias and Montessuit,
2013). In line with these aforementioned reports, we measured
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increased phosphorylated STAT3 content in the nuclear fraction
of the SKM cells with IL-15 induction. Thus, translocation of
STAT3, following phosphorylation at Tyr705, to the nucleus is
an indicator of its transcriptional activity and is the potential
route by which IL-15 promotes expression of genes associated
with metabolic activity (Bild et al., 2002; Yahata et al., 2003).
Since STAT3 activation has been associated with increases in
glucose metabolism, our data provides a link for IL-15 induced
metabolic function through Jak3/STAT3 signaling (Cui et al.,
2004; Frias and Montessuit, 2013; Richard and Stephens, 2014).
On the other hand, it has been suggested that STAT3-SOCS3
signaling stimulates insulin resistance in high fat diet induced
obesity (Wunderlich et al., 2013). However, we can rule out
SOCS3 as a player in the IL-15 signaling pathway, in regards to
glucose metabolism, as its expression levels remained unchanged
in the presence of IL-15. Adding to the controversy, when
STAT3 was knocked out of skeletal muscle, in mice, there were
no effects on whole body insulin tolerance, glucose uptake, fat
oxidation, physical activity, or body weight (White et al., 2015).
Nevertheless, here we can conclude, based on our data, that
STAT3 activation, via IL-15, is indeed involved in mediating
glucose uptake in SKM myotubes. Here we show that HIF1α, an
established downstream target of STAT3, andmediator of glucose
uptake and GLUT4 translocation, may be the link between IL-15-
Jak3/STAT3 and glucose uptake (Demaria et al., 2010; Sakagami
et al., 2014).
Taken together, it is clear that downstream effects of the IL-15
signaling pathway, required to carry out its beneficial effects on
metabolism, are complex and convoluted. Data presented here
provide evidence for direct regulation of IL-15 on glucose uptake
in SKM cells. Additionally, we solidify a signaling mechanism for
IL-15 action, through activation of Jak3 to ultimately activate and
promote STAT3 translocation to the nucleus. We propose a novel
signaling mechanism for IL-15 mediated increases in glucose
uptake and GLUT4 translocation via nuclear translocation of
STAT3. Further studies are essential to firmly establish the
unknown factors involved in the IL-15-Jak3/STAT3 signaling
axis for the potential treatment and/or prevention of metabolic
disorders, such as insulin resistance or diabetes.
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